Ipsen
Ipsen S.A., a global biopharmaceutical group headquartered in France, has established itself as a leader in the healthcare industry since its founding in 1929. With a strong presence in Europe, North America, and Asia, Ipsen focuses on innovative treatments in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Cabometyx®, which are distinguished by their unique mechanisms of action and efficacy in treating complex conditions. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. Recognised for its dedication to patient care and innovation, Ipsen continues to make strides in the biopharmaceutical sector, contributing to advancements that improve the quality of life for patients worldwide.
DitchCarbon Score
How does Ipsen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen's score of 37 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ipsen's reported carbon emissions
In 2023, Ipsen reported total greenhouse gas emissions of approximately 11,516,000 kg CO2e for Scope 1, 658,800 kg CO2e for Scope 2 (market-based), and about 21,248,000 kg CO2e for Scope 3 emissions. This reflects a commitment to reducing its carbon footprint significantly. Ipsen has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2019 as the base year. Additionally, the company aims to achieve a 20% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are consistent with efforts to limit global warming to 1.5°C. Over the years, Ipsen has demonstrated a commitment to sustainability, with emissions from Scope 1 decreasing from approximately 14,316,000 kg CO2e in 2019 to 11,516,000 kg CO2e in 2023. Scope 2 emissions also saw a reduction from about 4,343,000 kg CO2e in 2019 to 658,800 kg CO2e in 2023 (market-based). Ipsen's proactive approach to climate commitments reflects its dedication to environmental responsibility within the pharmaceutical and biotechnology sector, aiming for a sustainable future while addressing the challenges of climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 14,316,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,343,000 | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | 29,861,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipsen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
